U.S. Markets closed

Need To Know: Correvio Pharma Corp. (TSE:CORV) Insiders Have Been Selling Shares

Simply Wall St

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in Correvio Pharma Corp. (TSE:CORV).

Do Insider Transactions Matter?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, most countries require that the company discloses such transactions to the market.

We don’t think shareholders should simply follow insider transactions. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

See our latest analysis for Correvio Pharma

Correvio Pharma Insider Transactions Over The Last Year

While no particular insider transaction stood out, we can still look at the overall trading.

David McMasters ditched 19.60k shares over the year. The average price per share was US$5.80. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

TSX:CORV Recent Insider Trading, March 14th 2019

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Correvio Pharma Insiders Bought Stock Recently

We saw some Correvio Pharma insider buying shares in the last three months. Chief Financial Officer Justin Renz shelled out US$58k for shares in that time. We like it when there are only buyers, and no sellers. However, in this case the amount invested recently is quite small.

Insider Ownership of Correvio Pharma

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Correvio Pharma insiders own 3.1% of the company, worth about CA$6.3m. We prefer to see high levels of insider ownership.

So What Do The Correvio Pharma Insider Transactions Indicate?

The recent insider purchase is heartening. However, the longer term transactions are not so encouraging. Neither the level of insider ownership, nor the transactions over the last twelve months inspire us, but we think the recent buying is positive. Of course, the future is what matters most. So if you are interested in Correvio Pharma, you should check out this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.